Skip to main content

Novel Rx

      It seems so simple. We should be able to use proteomics to better pick winners when it comes to b/tsDMARDs in RA.

      Why i
      1 year ago
      It seems so simple. We should be able to use proteomics to better pick winners when it comes to b/tsDMARDs in RA. Why is it hard? I guess: - theory ≠ practice - too many other factors - it's too easy not to Yet I hope/believe, one day we'll do better. #ACR23 ABST0427 @RheumNow https://t.co/5VBVp3KOJN
      If you're >65 years old & have new RA, you start a DMARD, right? At worst, sometime in the first year?

      US Medica
      1 year ago
      If you're >65 years old & have new RA, you start a DMARD, right? At worst, sometime in the first year? US Medicare data 2008-17 n=33,373 only 30% have a DMARD on file (of which bDMARD <10%) >5% on PNL alone Do we hate old people with RA?😔 @JihaRheum #ACR23 ABST0433 @RheumNow https://t.co/1CUXAh3fi0
      I underestimated how much joy not-bankrupting our healthcare system would bring me

      ADA & RTX biosimilars have been
      1 year ago
      I underestimated how much joy not-bankrupting our healthcare system would bring me ADA & RTX biosimilars have been wonderful; excited for IL6's to join the party @RheumNow #ACR23 Abstr0445 https://t.co/HGwi37rZpd
      Year in Review by Dr. P Seo

      NORD-STAR trial:
      ⭐️Abatacept or Certolizumab >> Tociluzumab > triple therap
      Year in Review by Dr. P Seo NORD-STAR trial: ⭐️Abatacept or Certolizumab >> Tociluzumab > triple therapy in tx of 812 early RA patients based on clinical & radiographic results ➡️tx-naive, all got MTX ➡️mod-sev dz activity ➡️randomized to 48 wks therapy #ACR23 @RheumNow https://t.co/vy2uYuyOse
      Interesting question... but feels like some time related bias or perhaps confounding?

      Seems implausible that MTX &
      1 year ago
      Interesting question... but feels like some time related bias or perhaps confounding? Seems implausible that MTX & biologic would be protective for PsO & harmful for PsA @RheumNow #ACR23 Abstr 0498 https://t.co/pSRoLHRTAm
      C-VIEW study on certolizumab use in preventing anterior uveitis in high risk pts with axSpA.
      All pts were B27+ w/ at lea
      1 year ago
      C-VIEW study on certolizumab use in preventing anterior uveitis in high risk pts with axSpA. All pts were B27+ w/ at least one episode of anterior uveitis Uveitis flares lower in certolizumab group compared to non-bDMARD use @RheumNow #ACR23 Abs#0524 https://t.co/CfnhzStBMv
      You should not tire of hearing this! Phase2 RCT of #dazodalibep -CD40L antagonist for #extra glandular & could also
      1 year ago
      You should not tire of hearing this! Phase2 RCT of #dazodalibep -CD40L antagonist for #extra glandular & could also have #glandular problems in #Sjogrens was + improving Facit #fatigue & ESSPRI, etc. #GameChanger #ACR23 #ACRbest ⁦@ACRheum⁩ ⁦@RheumNow⁩ Pos#L10 https://t.co/DfChrAyslL
      We have made amazing strides in the treatment of rheumatoid arthritis with a plethora of highly effective treatments now in our armamentarium. The window of opportunity concept in RA then shifted our…
      Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab…
      For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy.…